These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 17603221

  • 1. Effect of benidipine on simvastatin metabolism in human liver microsomes.
    Sugiyama Y, Mimura N, Kuwabara T, Kobayashi H, Ushiki J, Fuse E.
    Drug Metab Pharmacokinet; 2007 Jun; 22(3):199-205. PubMed ID: 17603221
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine.
    Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S.
    Chem Biol Interact; 2019 Jun 01; 306():1-9. PubMed ID: 30965050
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.
    Yeo KR, Yeo WW.
    Br J Clin Pharmacol; 2001 May 01; 51(5):461-70. PubMed ID: 11422004
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
    Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T.
    Eur J Clin Pharmacol; 2000 May 01; 55(11-12):843-52. PubMed ID: 10805063
    [Abstract] [Full Text] [Related]

  • 8. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.
    Lilja JJ, Kivistö KT, Neuvonen PJ.
    Clin Pharmacol Ther; 2000 Oct 01; 68(4):384-90. PubMed ID: 11061578
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions.
    Uesawa Y, Takeuchi T, Mohri K.
    Curr Pharm Biotechnol; 2012 Jul 01; 13(9):1705-17. PubMed ID: 22039822
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.
    Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y.
    Drug Metab Dispos; 2001 Mar 01; 29(3):282-8. PubMed ID: 11181496
    [Abstract] [Full Text] [Related]

  • 15. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS, Galetin A, Hallifax D, Houston JB.
    Clin Pharmacokinet; 2006 Mar 01; 45(10):1035-50. PubMed ID: 16984215
    [Abstract] [Full Text] [Related]

  • 16. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
    Wang YH, Jones DR, Hall SD.
    Drug Metab Dispos; 2004 Feb 01; 32(2):259-66. PubMed ID: 14744949
    [Abstract] [Full Text] [Related]

  • 17. Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes.
    Ishigami M, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y.
    Drug Metab Dispos; 2002 Aug 01; 30(8):904-10. PubMed ID: 12124308
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins.
    Zhang B, Zhan G, Fang Q, Wang F, Li Y, Zhang Y, Zhao L, Zhang G, Li B.
    Mol Med Rep; 2019 Nov 01; 20(5):4713-4722. PubMed ID: 31545497
    [Abstract] [Full Text] [Related]

  • 19. The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
    Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, Matsubara M.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):49-55. PubMed ID: 20307534
    [Abstract] [Full Text] [Related]

  • 20. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
    Watanabe A, Kotsuma M.
    Drug Metab Pharmacokinet; 2024 Apr 10; 55():101000. PubMed ID: 38458122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.